Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

2,640

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

Flublok

A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Flublok is produced using recombinant technology under serum-free conditions.

BIOLOGICAL

Afluria

Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.

Trial Locations (14)

13901

Regional Clinical Research, Binghamton

27612

Wake Research, Raleigh

31406

Meridian Clinical Research, Savannah

33134

Clinical Research of South Florida, Coral Gables

44122

Rapid Medical Research, Inc., Cleveland

67207

Heartland Research Associates, LLC, Wichita

68164

Meridian Clinical Research, Omaha

70006

Benchmark Research, Metairie

75234

Research Across America, Dallas

76135

Benchmark Research, Fort Worth

76904

Benchmark Research, San Angelo

89104

Clinical Research Center of Nevada, LLC, Las Vegas

85704-1152

Genova Clinical Research, Tucson

04210

Maine Research Associates, LLC, Auburn

All Listed Sponsors
lead

Protein Sciences Corporation

INDUSTRY

NCT01825200 - Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age | Biotech Hunter | Biotech Hunter